Siemens CEO Roland Busch Eyes Acquisitions in AI, Life Sciences, and Operations Software

January 07, 2026
Siemens CEO Roland Busch said the company is exploring potential acquisitions in artificial intelligence, life sciences, and operations software, building on its $5.1 billion purchase of Dotmatics last year to strengthen AI-driven drug development and data infrastructure.

At the 2026 CES event in Las Vegas, Siemens AG Chief Executive Officer Roland Busch said the company is considering new acquisitions in artificial intelligence, life sciences, and operations software. These areas are seen as key to expanding Siemens’ technology portfolio in industrial and scientific applications.

Busch referenced the company’s $5.1 billion acquisition of Dotmatics in 2025, which has supported Siemens’ efforts in AI-driven drug development. He emphasized that building a strong data backbone for life sciences remains a strategic priority for the company.

The comments highlight Siemens’ continued focus on integrating AI across its business units, particularly in software systems that manage and optimize factory operations and scientific research processes.

We hope you enjoyed this article.

Subscribe to AI Funding Brief

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more